Summary of TEAEs reported during 101HEMB02
| . | Cohort 1 n = 3 . | Cohort 2 n = 3 . | Overall N = 6 . |
|---|---|---|---|
| 101HEMB01 | |||
| TEAE | 3 (100) | 3 (100) | 6 (100) |
| Related TEAE | 1 (33.3) | 3 (100) | 4 (66.7) |
| SAE | 1 (33.3) | 0 | 1 (16.7) |
| Related SAE | 0 | 0 | 0 |
| TEAE leading to discontinuation | 0 | 0 | 0 |
| TEAE leading to death | 0 | 0 | 0 |
| 101HEMB02 | |||
| TEAE | 3 (100) | 3 (100) | 6 (100) |
| Related TEAE | 1 (33) | 0 | 1 (17) |
| SAE | 1 (33) | 1 (33) | 2 (33) |
| Related SAE | 0 | 0 | 0 |
| TEAE leading to discontinuation | 0 | 0 | 0 |
| TEAE leading to death | 0 | 0 | 0 |
| . | Cohort 1 n = 3 . | Cohort 2 n = 3 . | Overall N = 6 . |
|---|---|---|---|
| 101HEMB01 | |||
| TEAE | 3 (100) | 3 (100) | 6 (100) |
| Related TEAE | 1 (33.3) | 3 (100) | 4 (66.7) |
| SAE | 1 (33.3) | 0 | 1 (16.7) |
| Related SAE | 0 | 0 | 0 |
| TEAE leading to discontinuation | 0 | 0 | 0 |
| TEAE leading to death | 0 | 0 | 0 |
| 101HEMB02 | |||
| TEAE | 3 (100) | 3 (100) | 6 (100) |
| Related TEAE | 1 (33) | 0 | 1 (17) |
| SAE | 1 (33) | 1 (33) | 2 (33) |
| Related SAE | 0 | 0 | 0 |
| TEAE leading to discontinuation | 0 | 0 | 0 |
| TEAE leading to death | 0 | 0 | 0 |
Data are presented as n (%).